You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Johnson and Johnson
Baxter
AstraZeneca
Express Scripts

Last Updated: April 17, 2021

DrugPatentWatch Database Preview

Botulinum toxin type b - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for botulinum toxin type b

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Centre Hospitalier Universitaire VaudoisPhase 4
Brigitte SchürchPhase 4
Dominik EttlinPhase 4

See all botulinum toxin type b clinical trials

Recent Litigation for botulinum toxin type b

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Halozyme, Inc. v. Lee2016-12-18

See all botulinum toxin type b litigation

Pharmacology for botulinum toxin type b

Company Disclosures: US Patents for botulinum toxin type b

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08   Start Trial Allergan, Inc. (Irvine, CA) 2013-06-10 RX company
Elan Pharm MYOBLOC botulinum toxin type b VIAL 103846 001 2000-12-08   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for botulinum toxin type b

These patents were identified by searching patent claims

Supplementary Protection Certificates for botulinum toxin type b

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016 00031 Denmark   Start Trial PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326
/2013 Austria   Start Trial PRODUCT NAME: BOTULINUMTOXIN TYP A; NAT. REGISTRATION NO/DATE: 1-23699, 2-00358, 2-00381 20121220; FIRST REGISTRATION: GB PL00426/0074-0105, PL00426/0118-0025, PL00426/0119-0007 20100708
2008000043 Germany   Start Trial PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531
2016000070123 Italy   Start Trial PRODUCT NAME: RITUXIMAB IN ASSOCIAZIONE CON IALURONIDASI RICOMBINANTE UMANA - SOLUZIONE PER INIEZIONE SOTTOCUTANEA(MABTHERA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/98/067/001-003, 20140326
2010901814274 Italy   Start Trial AUTHORISATION NUMBER(S) AND DATE(S): EU/1/00/166/001-003, 20010122
13/025 Ireland   Start Trial PRODUCT NAME: BOTULINUM TOXIN TYPE A; NAT REGISTRATION NO/DATE: PA0148/060/001 20130117; FIRST REGISTRATION NO/DATE: PA018/060/002 17/01/2013 IRELAND PA0148/060/003 17/01/2013 FINLAND 25162 16/01/2013 FINLAND 15424 16/01/2013 FINLAND 28146 20130116
2008000042 Germany   Start Trial PRODUCT NAME: CLOSTRIDIUM BOTULINUM NEUROTOXIN TYP A (150KD), FREI VON KOMPLEXPROTEINEN; REGISTRATION NO/DATE: 57093.00.00 20050531
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Mallinckrodt
Medtronic
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.